हिंदी साहित्य: पेन ड्राइव कोर्स
This just in:

Indian Economy

Shortcomings of Indian Chemical Industry: TIFAC

  • 20 Aug 2020
  • 4 min read

Why in News

Recently, a report by the Technology Information Forecasting and Assessment Council (TIFAC) has highlighted the shortcomings of the Indian chemical industry which prove to be barriers in competing with China.

  • TIFAC is an autonomous organisation and think-tank of the Department of Science and Technology and it commissioned the report in March 2020 when the Covid-19 pandemic had started accelerating in India.

Key Points

  • India does not have enough technology, plants and infrastructure to manufacture key chemicals in a cost-effective and less polluting manner.
  • India has nearly stopped manufacturing several key Active Pharmaceutical Ingredients (API).
    • India has given up the manufacturing of APIs for ascorbic acid, aspartame and antibiotics like rifampicin, doxycycline, tazobactam acid and even steroids.
    • Production of intermediates such as atorvastatin, chloroquine, gabapentin, ciprofloxacin, cephalosporins, immunosuppressants has also been stopped.
  • India depends on China for 67% of chemical intermediates and API that it needs to manufacture drugs and export.
    • India also depends on the USA and Italy for API.
  • The chemical industry is almost entirely dependent on China for chloroquine and hydroxychloroquine (HCQ).
  • Manufacturers are unable to meet the price at which chemicals are produced by China.
    • Solvent and chemicals manufacturing costs in India are over 15% more than in China.
  • The share of Indian bulk drugs and intermediates in the total pharmaceutical export mix reduced to 20% in 2018 from 42% in 2008.

Active Pharmaceutical Ingredients

  • These are significant ingredients in the manufacturing of drugs and are also called bulk drugs.
  • The Hubei province of China is the hub of the API manufacturing industry.

Pharmaceutical Intermediates

  • These are chemical compounds which form the building blocks of the APIs and are produced as a by-product during the production of API.


  • Need for mission mode chemical engineering with defined targets for uninterrupted synthesis of API molecules.
  • Creation of mega drug manufacturing clusters with common infrastructure in India.
  • Development of a technology platform for biocatalysis for cost optimization and investing in the fermentation sector of large capacity.
    • Biocatalysis refers to the use of natural substances from biological sources (such as enzymes) to speed up (catalyze) chemical reactions.
  • Government encouragement for Indian companies working in chemical segments.

Way Forward

SMS Alerts

Please login or register to view note list


Please login or register to list article as bookmarked


Please login or register to make your note


Please login or register to list article as progressed


Please login or register to list article as bookmarked